Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy’s have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk’s patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India’s growing metabolic disorder crisis.
No valid response from Gemini.
